Just copied and pasted a post of mols from iii site, as follows.......................... Excerpt from MF - not that i follow them but it's still publicity ReNeuron is expected to post annual losses in the region of £10m through to its financial year ending 31 March 2016, but is forecast to post a £26m profit the following year. ReNeuron's P/E is similar to that of Oxford Pharmascience, adjusting for ReNeuron's later move to profitability. I'll take that in 2017! 2016 in accordance with Edison mol
Woodford seems doing a lot of
marketing atm, pity his choice of share(RENE) doesnot move. Look, if his shares are all moving in the right direction, no need for marketing, people will throw money at him. And another thing I notice, that Harper is the board member of RENE, just watch out, he is board member for other two companies both became worthless, I hope his bad luck won't rub on here.
24 Feb '15
many thanks lostagain
I will look out for him 'smiler' in future. Best wishes. Freddie
24 Feb '15
I think it is the nick name given to Prof Dave Cole , who has been studying reneuron for the last 4 years and has recently trebled his stake When is the next date of trial results. Does someone know something. The Pof was unavailable for comment , He was out building or so his secretary or P A assured me
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.